In the Claims:

1. (Previously Presented) A compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof in which:

X is selected from the group consisting of oxygen and NR^2;

Y is CH;

R^1 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylOC_{1-3}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-10}cycloalkylC_{0-6}alkyl, C_{4-7}cycloalkyl substituted by C_{1-3}alkyl or C_{1-3}alkoxy, C_{4-12}bridged cycloalkyl, and $A(CR^6R^7)_n$;

R^2 is selected from the group consisting of H and C_{1-6}alkyl;

R^3 is selected from the group consisting of C_{1-5}alkyl and C_{1-2}alkyl substituted by one to five fluorine atoms;

R^4 is selected from the group consisting of C_{1-6}alkyl, NH_2 and R^9CONH;

R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylO_2C, halogen, cyano, $(C_{1-3}alkyl)_2NCO$, C_{1-3}alkylS and C_{1-3}alkylO_2S;

R^6 and R^7 are independently selected from H and C_{1-6}alkyl;

A is an unsubstituted 6-membered aryl, or a 6-membered aryl substituted by one or more R^8;

R^8 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, C_{1-6}alkoxy substituted by one or more F, NH_2SO_2 and C_{1-6}alkylSO_2;

R^9 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylOC_{1-6}alkyl, phenyl, HO_2CC_{1-6}alkyl, C_{1-6}alkyl$OCOC_{1-6}$alkyl, C_{1-6}alkylOCO, H_2NC_{1-6}alkyl, C_{1-6}alkyl$OCONHC_{1-6}$alkyl and

C_{1-6}alkylCONHC_{1-6}alkyl;

R^{10} is selected from the group consisting of H and halogen; and

n is 0 to 4.

2. (Currently Amended) The compound of claim 1

or a pharmaceutically acceptable salt thereof, wherein

R^1 is selected from the group consisting of H, C_{1-6}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylOC_{1-3}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-10}cycloalkylC_{0-6}alkyl, C_{4-12}bridged cycloalkyl, and $A(CR^6R^7)_n$; and,

R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, halogen, cyano, $(C_{1-3}alkyl)_2NCO$, C_{1-3}alkyl$S$ and C_{1-3}alkylO_2S ;.

3. (Previously Presented) The compound of claim 1

or a pharmaceutically acceptable salt thereof wherein

n is 1 to 4.

4. (Previously Presented) A compound as claimed in claim 1 wherein:

X is oxygen;

Y is CH;

R^1 is $A(CR^6R^7)_n$;

R^3 is selected from the group consisting of C_{1-5}alkyl and C_{1-2}alkyl substituted by one to five fluorine atoms;

R^4 is C_{1-6}alkyl;

R^5 is selected from the group consisting of hydrogen, C_{1-3}alkyl, C_{1-2}alkyl substituted by one to five fluorine atoms, C_{1-3}alkylO_2C, halogen, and C_{1-3}alkyl$S$;

A is an unsubstituted 6-membered aryl, or a 6-membered aryl substituted by one or more R^8;

R^8 is selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkyl substituted by one more fluorine atoms, C_{1-6}alkoxy, and C_{1-6}alkoxy substituted by one or more F;

R^{10} is selected from the group consisting of H and halogen; and
n is 0.

5. (Canceled)

6. (Currently Amended) A compound selected from the group consisting of:

N-(cyclohexylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-cyclohexyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-cycloheptyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-(cis-4-methylcyclohexyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

N-(1-ethylpropyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine; and

N-(cyclopentylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine.

7. (Withdrawn and Currently Amended) A process for the preparation of a compound as defined in claim 1 which comprises reacting a compound R^1XH , or a protected derivative thereof, with a compound of formula (III)



(III)

where R^1 , R^3, R^4, R^5, ~~and~~ X, and Y are as defined in claim 1 and Z is halogen or a sulfonate, and thereafter and if necessary, interconverting a compound of formula (I) into another compound of formula (I), and/or deprotecting a protected derivative of compound of formula (I).

8. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.

9. (Canceled)

10. (Canceled).

11. (Canceled).

12-13. (Canceled)

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Currently Amended) A method of treating an animal subject suffering from ~~The method according to claim 11, wherein said condition is~~ rheumatoid arthritis mediated by COX-2, which method comprises administering to said subject an effective amount of a compound as claimed in claim 1.

18. (Currently Amended) A method of treating an animal subject suffering from ~~The method according to claim 11, wherein said condition is~~ osteoarthritis mediated by COX-2 , which method comprises administering to said subject an effective amount of a compound as claimed in claim 1.

19. (Canceled).

20. (Canceled).

21. (Canceled).

22. (Canceled).

23. (Canceled).

24. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 2 in admixture with one or more physiologically acceptable carriers or excipients.

25. (Canceled).

26. (Canceled).

27. (Previously Presented) N-cyclohexyl-4-(trifluoromethyl)-6-[4-methylsulfonyl)phenyl]pyridine-2-amine or a pharmaceutically acceptable salt thereof.